CLSPN and familial pancreatic carcinoma: Further study revealed that celastrol treatment downregulated Claspin and Bcl-2 in an m6A-YTHDF3-mediated manner, which providing a novel mechanism for the therapeutic application of celastrol in pancreatic cancer.